Ipsen : and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson's disease -Today at 11:02 am
Ipsen obtains the exclusive worldwide rights to develop and commercialize the investigational treatment mesdopetam which is based on a novel mechanism of action ...